Possible scenario
Defensive Read-Through
25% Chance
The transaction is interpreted less as a breakthrough and more as evidence that Novo's internal oral obesity pipeline remains weaker than investors hoped. Lilly benefits from the comparison because its oral GLP-1 pill already produced positive data in 2025.
Secondary impacts
- Healthcare -0.2%
Tickers
- LLY+1.3%
Portfolio impact
S&P 500+0.0%
Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.
Keeping an eye on this scenario?
Tilt can alert you when its probability or impact shifts, or send you a recommendation when it crosses a threshold.